source
- Beyond GLP-1s: Companies eye new obesity drug mechanisms as efficacy plateausThe obesity drug market continues to expand, with GLP-1 therapies growing from about $5.5 billion in 2023 to over $55 billion projected for 2033. These agents are used for weight loss, diabetes and…
- Ultragenyx's Angelman syndrome drug fails in Phase 3 trial, showing no benefitUltragenyx announced that its experimental therapy GTX-102 for Angelman syndrome did not demonstrate any benefit compared with a sham control in a large Phase 3 trial. The drug had previously show…